(VIANEWS) – HomeTrust Bancshares (HTBI), Novo Nordisk A/S (NVO), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. HomeTrust Bancshares (HTBI)
35.4% sales growth and 8.35% return on equity
HomeTrust Bancshares, Inc. operates as the bank holding company for HomeTrust Bank that provides a range of retail and commercial banking products and services. Its deposit products include savings, money market, and demand accounts, as well as certificates of deposit for individuals, businesses, and nonprofit organizations. The company's loan portfolio comprises retail consumer loans, such as one-to-four-family real estate lending, home equity lines of credit, construction and land/lots, indirect auto finance, and consumer lending; and commercial loans that include commercial real estate lending, construction and development lending, and commercial and industrial loans. It also provides small business administration loans, equipment finance leases, indirect automobile loans, and municipal leases; and cash management and online/mobile banking services. As of June 30, 2020, the company operated 41 offices in North Carolina, Upstate South Carolina, East Tennessee, and Southwest Virginia. HomeTrust Bancshares, Inc. was founded in 1926 and is headquartered in Asheville, North Carolina.
Earnings Per Share
As for profitability, HomeTrust Bancshares has a trailing twelve months EPS of $2.27.
PE Ratio
HomeTrust Bancshares has a trailing twelve months price to earnings ratio of 9.63. Meaning, the purchaser of the share is investing $9.63 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.35%.
Moving Average
HomeTrust Bancshares’s value is higher than its 50-day moving average of $20.89 and under its 200-day moving average of $23.73.
2. Novo Nordisk A/S (NVO)
22.4% sales growth and 83.5% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $4.06.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 39.06. Meaning, the purchaser of the share is investing $39.06 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 83.5%.
3. Exelixis (EXEL)
14.3% sales growth and 6.34% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.47.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 41.26. Meaning, the purchaser of the share is investing $41.26 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.34%.
Previous days news about Exelixis(EXEL)
- According to Zacks on Monday, 31 July, "Pfizer(PFE Quick QuotePFE – Free Report) , Merck (MRK Quick QuoteMRK – Free Report) , Vertex Pharmaceuticals (VRTX Quick QuoteVRTX – Free Report) , Exelixis (EXEL Quick QuoteEXEL – Free Report) and Incyte (INCY Quick QuoteINCY – Free Report) are scheduled to release second-quarter earnings on Aug 1. ", "For the quarter to be reported, Exelixis has an Earnings ESP of -21.94% and a Zacks Rank #2. "
- Exelixis (exel) reports Q2 earnings: what key metrics have to say. According to Zacks on Tuesday, 1 August, "Here is how Exelixis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:"
- Exelixis (exel) Q2 earnings top, cabometyx drives growth. According to Zacks on Wednesday, 2 August, "Under this program, Exelixis repurchased $127.0 million of the company’s common stock at an average price of $19.22 per share as of Jun 30.", "In July, Exelixis announced that it entered into a settlement and license agreement with Teva Pharmaceuticals (TEVA Quick QuoteTEVA – Free Report) . "
4. Aercap Holdings N.V. Ordinary Shares (AER)
13.1% sales growth and 11.12% return on equity
AerCap Holdings N.V., an aircraft leasing company, engages in the lease, financing, sale, and management of commercial aircraft and engines in China, the United States, Ireland, and internationally. The company offers aircraft asset management services, including remarketing aircraft; collecting rental and maintenance rent payments, monitoring aircraft maintenance, monitoring and enforcing contract compliance, and accepting delivery and redelivery of aircraft; and conducting ongoing lessee financial performance reviews. Its aircraft asset management services also comprise periodically inspecting the leased aircraft; coordinating technical modifications to aircraft to meet new lessee requirements; conducting restructuring negotiations in connection with lease defaults; repossessing aircraft; arranging and monitoring insurance coverage; registering and de-registering aircraft; arranging for aircraft and aircraft engine valuations; and providing market research services. The company also provides cash management services, including treasury services, such as the financing, refinancing, hedging, and ongoing cash management of vehicles; and administrative services comprising accounting and corporate secretarial services consisting of the preparation of budgets and financial statements. As of December 31, 2018, it had a portfolio of 1,421 owned, managed, or on order aircraft. AerCap Holdings N.V. was founded in 1995 and is headquartered in Dublin, Ireland.
Earnings Per Share
As for profitability, Aercap Holdings N.V. Ordinary Shares has a trailing twelve months EPS of $7.02.
PE Ratio
Aercap Holdings N.V. Ordinary Shares has a trailing twelve months price to earnings ratio of 9.1. Meaning, the purchaser of the share is investing $9.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.12%.
5. Apollo Medical Holdings (AMEH)
9.3% sales growth and 9.51% return on equity
Apollo Medical Holdings, Inc., a physician-centric technology-powered healthcare management company, provides medical care services. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The company's physician network consists of primary care physicians, specialist physicians, and hospitalists. It serves patients, primarily covered by private or public insurance, such as Medicare, Medicaid, and health maintenance organization plans; and non-insured patients in California. The company was founded in 1994 and is headquartered in Alhambra, California.
Earnings Per Share
As for profitability, Apollo Medical Holdings has a trailing twelve months EPS of $1.08.
PE Ratio
Apollo Medical Holdings has a trailing twelve months price to earnings ratio of 31.92. Meaning, the purchaser of the share is investing $31.92 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.51%.
6. Owens (OI)
6.2% sales growth and 47.84% return on equity
O-I Glass, Inc., through its subsidiaries, engages in the manufacture and sale of glass containers to food and beverage manufacturers primarily in the Americas, Europe, and internationally. The company produces glass containers for alcoholic beverages, including beer, flavored malt beverages, spirits, and wine. It is also involved in the production of glass packaging for various food items, soft drinks, tea, juices, and pharmaceuticals. In addition, the company offers glass containers in a range of sizes, shapes, and colors. It sells its products directly to customers under annual or multi-year supply agreements, as well as through distributors. The company was founded in 1903 and is headquartered in Perrysburg, Ohio.
Earnings Per Share
As for profitability, Owens has a trailing twelve months EPS of $4.36.
PE Ratio
Owens has a trailing twelve months price to earnings ratio of 5.28. Meaning, the purchaser of the share is investing $5.28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 47.84%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 13.7% and 1.6%, respectively.
Moving Average
Owens’s value is above its 50-day moving average of $21.74 and way above its 200-day moving average of $19.97.
Sales Growth
Owens’s sales growth is 3.7% for the current quarter and 6.2% for the next.
